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Conclusion: TAD measurement in A4C view by 2D-TTE was highly
feasible, reproducible and accurately reflected TA size, even if it was sys-
tematically underestimating its maximal diameter. Based on measurements
in healthy volunteers, we suggest to consider tricuspid annuloplasty during
left-heart valve surgery when TA is more than 2.3cm/m² or 4.2cm in A4C. 
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Aims: To evaluate the prognostic impact of QRS width in patients with
low-flow/low-gradient aortic stenosis (LF/LGAS).
Methods and Results: Among 88 consecutive patients referred to our
institution for LF/LGAS from September 1994 to March 2007, baseline demo-
graphic, clinical, echocardiographic and electrocardiographic data were col-
lected. This population was divided in two groups according to baseline QRS
duration (cutoff: QRS≥ 130ms). Follow-up data, including electrocardio-
graphic evolution and overall mortality were analyzed. The mean follow-up
duration was 3.1 (2.2-6.2) years. In the whole group, 67 patients underwent
surgical aortic valve replacement. Forty-nine patients (56%) had a QRS dura-
tion≥ 130ms. Among operated patients, there was no significant change in
QRS duration between baseline and latest follow-up (126±26 vs. 131±25ms;
p=0.82). In addition, wider QRS was a strong independent predictor of overall
mortality [HR=2.20; CI, 1.15–4.24; p=0.027]. 
Conclusion: Significant intra-ventricular conduction disturbances are
common in patients with LF/LGAS and do not recover after aortic valve
replacement. QRS duration is strongly associated with mortality in this
selected population.
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Objective: Describe the immediate and final outcome of percutaneous
mitral balloon commissurotomy (PMC) with Inoue balloon in patients over
50 years old and associate complications with age and Wilkins score.
Material and methods: A retrospective and analytic study was
performed with a data base of 480 patients. We included all the patients
proceeding in our department from January 1998 to December 2012. 75
were > or = 50-years old (group1). Immediate and late outcomes in this
group (group 1) were compared with those in the patients aged < 50-years
(group 2).
Results: Baseline hemodynamic parameters were comparable in the
two groups. The Wilkins score was> 8 in 11 patients We found a Mitral
Valvular Area (MVA) before the PMC proceeding of 0.99cm2±0.2 and
1.87cm2±0.38 post PMC (P < 0.001), with pre procedure transmitral gra-
dient of 12.7±4.05mm Hg and of 4.4±2.3mm Hg post (P < 0.001). Similar
significant improvements were seen in group 2. In 72 patients (96%) the
immediate proceeding was considered successful.The hemodynamic result
was good in 85.3% of group 1 patients. Tamponade occurred in one
patient. Mitral regurgitation grade I or II developed in 8 patients and
remained stable in 19 patients. These complication rates were comparable
to those seen in group 2. A clinical and echocardiographic follow-up was
performed in 68 patients (93%). In the group 1, a good result was main-
tained in 60% of patients after 75.8±40 months of follow-up. Although
restenosis was observed in 28% of patients, functional amelioration was
obtained in most of cases. Survival free of mitral valve intervention or
heart failure ≥ NYHA III was significantly better for patients with good
immediate result.
Conclusions: PMC is safe and efficacious in elderly patients with symp-
tomatic mitral stenosis. Long-term results are good and related mainly to the
quality of the procedure. 
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Background: Aortic stenosis (AS) is increasing in incidence with the
aging of the population. Transcatheter Aortic Valve Implantation (TAVI)
provides a therapeutic option for patients with severe AS who are high risk
surgical candidates A large proportion of patients undergoind TAVI have
at least mild aortic paravalvular regurgitation (APR) following the proce-
dure.
Objective: The purpose of this study was to determine the clinical and
prognostic significance of paravalvular regurgitation early after TAVI.
Methods: Hundred and five patients who underwent TAVI at our center
from 9.2008 to 5.2012 were studied retrospectively. Echocardiography
before and following the procedure but prior to discharge were reviewed.
Aortic and mitral regurgitations were assessed using semi quantitative
methods.
Results: Among 105 patients who underwent TAVI, twenty four (23%)
had significant (moderate and more) APR and eighty one (77%) had non sig-
nificant (less than moderate) APR. There was not significant difference in the
baseline characteristics of the two groups (age, sex, left ventricular ejection
fraction, aortic valve area, aortic ventricular gradient, ischemic heart disease,
pre-procedural aortic regurgitation). Mean follow up was up to 19 months.
The mortality rate was higher in the group with significant PAR as compared
with the group without APR (29% versus 11% p<0.009). The frequency of
develop block was more frequent in this group (47% versus 30%, p<0.205).
Worsening of Mitral regurgitation was more frequent in the significant APR
group (71% versus 17%, P<0.001) as worsening of pulmonary hypertension
(21% versus 4%, P<0.001).
Conclusions: Significant paravalvular aortic regurgitation after TAVI
causes worsening of mitral regurgitation and pulmonary hypertension and
seems associated with higher risk of pacemaker implantation and mortality.
Paravalvular aortic regurgitation has clinical significance beyond the often
minimal hemodynamic effects after TAVI. 
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Background: Percutaneous mitral valvuloplasty (PMV) has emerged as
the procedure of choice in treatment of mitral stenosis and has proved
effectiveness in cases of mitral restenosis after surgical commissurotomy
Compared with surgery, PMV is associated with shorter hospital stays,
reduced patient discomfort, and significantly lower costs. However, it is
unknown whether patients who developed symptomatic mitral restenosis after
PMV may benefit from repeat PMV (re-PMV) with safety. 
Objectives: This study was designed to evaluate the occurrence rate and
the predictive factors for severe complications following re-PMV. 
Methods: Retrospective study from a series of 40 procedures of re-PMV
with the Inoue balloon at 8±4 years after prior procedure, performed between
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1996 and 2011. A clinical and ultrasound follow-up was achieved in
31 patients with a mean follow-up period of 43±26 months. 
Results: The mean age of patients was 43±11 years [23, 63]. 87,5% of the
population being female (5 men and 35 women). The immediate procedural
success was achieved in 31 patients (77.5%). A severe mitral regurgitation
(MR) was observed in 3 patients (7.5%). A cerebrovascular stroke occurred in
1 patient (2.5%). No procedure-related death or cardiac tamponade were
noted. Only a left atrial area ≤25cm ² was linked to high risk of severe MR.
At long-term, mitral restenosis was observed in 13 patients (42%) at 53±30
months [9; 128] after re-PMV, 2 patients presented thromboembolic events (6%)
and no death. Only the male had been identified as a predictor of restenosis 
Conclusion: The feasibility of re – PMV with a relatively high procedural
success rate and an acceptable complication profile makes it an appealing
therapeutic strategy for patients with recurrent valve stenosis. The improved
experience of our medical teams, and the systematic use of transoesophageal
echocardiography to detect thrombi explain the low incidence of the compli-
cations of re-PMV in our study. 
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Aims: Benfluorex’s imputability in drug-induced valvular heart disease
(DIVHD) is now well established. However no data about long term clinical
and echocardiographic follow-up of patients suffering from benfluorex-
related DIVHD are available. The present study was conducted to address
this issue.
Methods and results: Between January 2003 and June 2012, after an
exhaustive analysis of our database, 20 patients (55±9 years, 90% women,
body mass index: 32.9±9 kg/m²) hospitalized for heart failure were retrospec-
tively identified with benfluorex induced moderate or severe mitral regurgita-
tion (MR). Initially 70% of them presented NYHA class III or IV. MR was
quantified as moderate in 11, moderate to severe in 8 and severe in one
patient. Aortic regurgitation (AR) was also present in 17 patients (85%): mild
in 5, moderate in 9 and moderate to severe in 3 patients. During a median
follow-up of 7 years, heart failure episodes led to 53388 Valve replacements.
Two patients died, one in the surgical group and one in the medical group.
Among survivors, NYHA class improved in 6 patients in the surgical group
but only in 4 in the medical group. After withdrawal of benfluorex, MR
decreased in 7 patients and AR decreased in 5 patients. MR was stable in
3 patients and AR in 4 patients. A worsening of MR was not observed and AR
worsened in 2 patients. 
Conclusion: After an hospitalization for a first episode of heart failure
related to benfluorex-induced MR, patients are exposed to a large number of
cardiac events including repeated hospitalizations and death. 
